According to the research reports of China Galaxy Securities, with the commercialization of semaglutide and tirzepatide, the market size of GLP-1 drugs worldwide is rapidly growing. Many enterprises are competing to expand their presence in the GLP-1 weight loss field, while the penetration rate of GLP-1 treatment in the blood sugar reduction field still has room for further improvement. It is recommended to pay attention to domestic GLP-1-related symbols such as Innovent Bio, Jiangsu Hengrui Pharmaceuticals, Brightgene Bio-Medical Technology Co.,Ltd., Gan & Lee Pharmaceuticals, and Huadong Medicine.
银河证券：全球GLP-1药物的市场规模迅速增长 推荐关注国产GLP-1相关标的
Galaxy Securities: The market size of global GLP-1 drugs is rapidly growing, recommended attention to domestic GLP-1 related symbols.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.